Start with the regulated decision

Use vibrational spectroscopy for identity, solid-form differentiation, raw-material ID, mapping, contaminant analysis, and method development.

For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.

FDA inspected laboratory iconFDA GMP laboratory icon

Overview of cGMP Raman and FTIR Services

What is this?

cGMP Raman and FTIR are vibrational spectroscopy methods used for chemical fingerprinting, raw-material identification, form differentiation, contaminant ID, and mixture or mapping applications.

When is it used?

Use Raman/FTIR when the quality question can be answered by molecular vibrations, spatial location, polymorph discrimination, component mapping, or a validated raw-material ID method.

What are limitations?

Spectra can be affected by fluorescence, water, particle size, orientation, matrix overlap, laser damage, pressure/contact artifacts, baseline correction, and spectral pre-processing choices.

What sample amounts are needed?

Amounts may be very small for ID, but method validation, calibration, detection-limit, mixture, and mapping studies require representative standards and matrix controls.

What techniques compete with it?

XRPD, NMR, HPLC/GC, MS, microscopy, SEM/EDX, DSC/TGA, and particle methods compete or complement Raman/FTIR depending on the sample and decision.

What does FDA care about?

FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.

What are common mistakes?

Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.

What is Triclinic's experience with this technique

Triclinic uses cGMP Raman and FTIR for regulated identity, material-comparison, contaminant, polymorph, and functional-group questions where spectral evidence must be collected and reviewed under controlled procedures. Real-world applications include raw-material identity support, release and stability testing, foreign-particle or residue investigations, and validated or verified methods that provide rapid orthogonal evidence for quality decisions.

What changes when the work is cGMP?

Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.

cGMP concernWhy it mattersPractical control
Method statusExploratory, verified compendial, validated custom, and transferred methods have different evidence requirements.Define status before testing and document any development, verification, validation, or transfer work.
Sample matrixSpecificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures.Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed.
Data integrityRelease or stability results must survive QA review, audit, and regulatory scrutiny.Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations.

Specific instruments and capabilities for cGMP Raman and FTIR Services

The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.

Instrument or platformBrand, model, software, or detectorAdditional capabilities and use
Dispersive Raman microscopyRenishaw inVia Raman microscope with DMLM Leica microscope, 785 nm laser, and CCD detectorChemical imaging, confocal microsampling, polymorph discrimination, carbon-nanotube characterization, and spatial component mapping.
FT-RamanThermo NXT FT-Raman module interfaced to Nicolet 6700 FT-IR spectrometer; 1064 nm Nd:YAG laser; InGaAs detector; OMNIC v.9.7.46 with spectral librariesMicro and macro Raman sampling, reduced fluorescence for selected samples, library matching, and non-destructive molecular fingerprinting.
Low-frequency RamanOndax THz-Raman system with probeStokes and anti-Stokes signals from +/-5 cm-1 to 200 cm-1, or 150 GHz to 6 THz, for lattice-mode/polymorph-sensitive measurements.
Infrared imagingThermo iN10 MX with Picta 1.5.141 softwareIR chemical imaging, ATR/reflection/transmission sampling, microsampling, real-time particle identification, and distribution mapping.
FT-IRThermo iS50 Model 60825 and Nicolet 6700; ATR, diffuse reflectance, transmission, gas cell; DTGS detector; OMNIC v.9.7.46 softwareFunctional-group identification, spectral-library matching, gas-cell/TGA-IR evolved-gas analysis, and organic/inorganic material identification.

Raman Chemical Imaging and FTIR Material Identification for Regulated Decisions

This example shows how vibrational spectroscopy can move from qualitative identification to spatially resolved product understanding. Raman and FTIR methods can support molecular fingerprinting, polymorph differentiation, raw-material identity, contaminant identification, and chemical imaging, but for cGMP use the spectral method must be specific for the matrix and validated, verified, or transferred for the decision it supports.

Raman chemical imaging map of a tablet surface
Raman chemical-imaging and component-distribution example. Chemical imaging can support questions about API distribution, blend uniformity, layered tablets, contaminants, microspheres, and counterfeit products, but the map must be interpreted through controlled spectral specificity, sampling, and data-processing procedures. Source: Triclinic Labs spectroscopy and chemical-imaging material.

Technical Resources and Publications

These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.

Application of Low-Frequency Raman Spectroscopy to an Isoenergetic Polymorph Study

Author: Triclinic Labs

Publication date: 2019

Abstract: This white paper describes how low-frequency Raman can distinguish polymorphic forms through lattice-mode information, making Raman an important orthogonal method for form ID and cGMP solid-mixture method development.

Download

Low-Frequency Raman Analysis of Spray-Dried Dispersions

Author: Triclinic Labs

Publication date: April 2023

Abstract: This application note combines dissolution, PXRD, and low-frequency Raman mapping to connect chemical identity, phase, and spatial distribution in formulation-relevant samples.

Download

ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development

Author: International Council for Harmonisation / FDA

Publication date: 2024

Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.

Download

NMR

Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.

View service

XRPD

Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.

View service

Morphology

Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.

View service

Common questions

When should cGMP Raman and FTIR Services be run under cGMP?

Run the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.

How much material should be submitted?

Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment.

Can Triclinic help choose the method?

Yes. The project should be scoped from the quality attribute, sample matrix, method status, and regulatory decision before selecting a technique or validation plan.

What makes the result defensible?

Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.

Do you develop, validate, and transfer methods?

Yes. Triclinic develops, validates, and transfers Raman, FTIR, ATR-FTIR, infrared-imaging, and Raman-mapping methods when spectral identity, polymorph discrimination, component distribution, contaminant identification, or release/stability decisions require controlled execution. Method work can include laser or optical configuration, spectral range, sample preparation, reference libraries, mapping parameters, specificity, chemometrics, precision, robustness, and transfer controls.

Can Raman or FTIR be used for raw-material identity testing?

Yes. Identity methods can be developed, verified, validated, or transferred when reference materials, spectral ranges, preprocessing, acceptance criteria, instrument configuration, sampling, and matrix or packaging effects are appropriately controlled.

Talk with Triclinic Labs

Discuss cGMP testing requirements

Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.

Discuss cGMP Testing